Pathogenesis and management of traumatic brain injury (TBI): role of neuroinflammation and anti-inflammatory drugs

Sunishtha Kalra1 · Rohit Malik1 · Govind Singh1 · Saurabh Bhatia2,3 · Ahmed Al-Harrasi3 · Syam Mohan2,4 · Mohammed Albratty5 · Ali Albarrati6 · Murtaza M. Tambuwala7

Abstract
Traumatic brain injury (TBI) is an important global health concern that represents a leading cause of death and disability. It occurs due to direct impact or hit on the head caused by factors such as motor vehicles, crushes, and assaults. During the past decade, an abundance of new evidence highlighted the importance of inflammation in the secondary damage response that contributes to neurodegenerative and neurological deficits after TBI. It results in disruption of the blood–brain barrier (BBB) and initiates the release of macrophages, neutrophils, and lymphocytes at the injury site. A growing number of researchers have discovered various signalling pathways associated with the initiation and progression of inflammation. Targeting different signalling pathways (NF-κB, JAK/STAT, MAPKs, PI3K/Akt/mTOR, GSK-3, Nrf2, RhoGTPase, TGF-β1, and NLRP3) helps in the development of novel anti-inflammatory drugs in the management of TBI. Several synthetic and herbal drugs with both anti-inflammatory and neuroprotective potential showed effective results. This review summarizes different signalling pathways, associated pathologies, inflammatory mediators, pharmacological potential, current status, and challenges with anti-inflammatory drugs.

Keywords Anti-inflammatory drugs · Clinical trial · Management · Neuroinflammation · Pathogenesis · Traumatic brain injury

Abbreviations
BBB Blood brain barrier
BDNF Bain-derived neurotrophic factor
COX Cyclooxygenase
ERK Extracellular signal-regulated protein kinase
GSK-3 Glycogen synthase kinase 3

1 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, India
2 School of Health Sciences, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India
3 Natural and Medical Sciences Research Centre, University of Nizwa, Birkat Al Mauz, Nizwa, Oman
4 Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia
5 Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia
6 Rehabilitation Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
7 School of Pharmacy and Pharmaceutical Sciences, Ulster University, Northern Ireland, UK
Clinical trials have failed due to the physiological variability improving long-term clinical outcomes. However, significant the ability to prevent and reduce secondary harm while also ops gives a golden chance for medical approaches that has 2008). The interval during which secondary injury devel -opment of safety devices (Werner and Engelhard 2007; Mbye et al. 2017). Onset of secondary injury is a result of primary injury. Primary injury is responsible for initiation of secondary injury. Secondary injury develops over a periods of time after primary injury (Hovda et al. 1994; Xiong et al. 1997; Singh et al. 2006). Secondary injury cascades include oxidative stress, endoplasmic reticulum stress, and neu-roinflammation contribute to long-term brain damage and neurological deficits after a TBI. Although most researchers have highlighted negative neuroinflammatory consequences on damaged brain, significant benefits can be obtained if neuroinflammation is treated in a controlled manner. We will look at synthetic and herbal anti-inflammatory drugs that have been explored as therapeutic options for TBI and have shown potential in clinical trials.

Neuroinflammation in pathogenesis of TBI

Neuroinflammation plays an important role in neurological impairments and neurodegeneration that might occur after TBI. Increased levels of inflammatory mediators, glial cell activation, and leukocyte recruitment are signs of post-traumatic neuroinflammation (Morganti-Kossmann et al. 2007).

TBI results in disruption of BBB, initiate release of macrophages, neutrophils, and lymphocyte at site of injury. Researchers, working on TBI in animals and humans, have observed an increase in blood-borne immune cells inside the brain parenchyma. Inflammatory mediators are released by these cells, which attract immune and glia cells to the injured area. In addition to immune cell invasion, resident microglia activation plays an important role in damage. Microglial processes form a first-line defence barrier between healthy and injured area of brain (Davalos et al. 2005; Haynes et al. 2006). Whenever microglia become excessively reactive or activated, they release oxidative metabolites (e.g. nitric oxide and reactive oxygen species) as well as pro-inflammatory cytokines [e.g. tumour necrosis factor α (TNF-α), interleukin (IL-1β)], and interferon γ (IFN-γ) that have a detrimental impact on neurons (Block and Hong 2005). Furthermore, production of pro-inflammatory cytokines and supplementary components determines the successive stimulation of astrocytes and glial scar formation in brain injury. Development of intermediary filaments (GFAP and vimentin), elevated cellular accumulation, and cell swelling are all signs of astrocyte activation (Herrmann et al. 2008).

Corresponding to microglia, reactive astrocytes also produce destractive as well as neuroprotective effects in TBI. Activation of astrocyte stimulates variety of neurotrophic factors like brain-derived neurotrophic factor (BDNF) to protect and support brain from cellular death persuaded by injury (Zhao et al. 2004). Moreover, astrocytes are important regulators of extracellular glutamate level and responsible for reducing glutamate excitotoxicity in neurons as well.
as neuroglia (Schousboe and Waagepetersen 2005). Particularly, damaged astrocytes aggravate transgenic depletion and neuronal deterioration of reactive astrocyte which consequently promotes neuronal death and assists terrible consequences following TBI (Maeda et al. 2003). Hypertrophic astrocytes around lesion site after damage form a suppressive extracellular matrix containing chondroitin sulphate proteoglycans, which prompt the formation of glial scar. The developed strong physiochemical barrier restricts functional connections needed for axonal repair and growth, as well as impedes axonal regeneration (Cafferty et al. 2007). Contrarily, astrocytes give nutritional guidance and support throughout axonal growth after neuronal injury, but chronic astrogliosis limits and impairs functional recovery and axon regeneration (Menet et al. 2003; Wilhelmsson 2004).

Inflammatory signalling pathways in pathogenesis of TBI

**Nuclear factor-kappa B (NF-kB)** NF-kB is an imperative inflammatory signalling pathway which involves in the synthesis of inflammatory molecules and pro-inflammatory genes such as cytokines and chemokines (Liu et al. 2017b). NF-kB is a downstream element for the stimulation of various receptors such as toll-like receptor 4 (TLR-4) and tumour necrosis factor receptor-associated factor6 (TRAF-6) in human and animals which suffered with TBI. As a consequence, inhibiting NF-kB reduces apoptosis and inflammation following injury. A previous study reported that NF-kB activation in glial and neuronal cells is associated with neuroprotective activity and neurodegenerative diseases (Singh and Singh 2020). In glial cells, NF-kB promotes inflammation, whereas in neurons it plays a role in synaptic plasticity, neuronal development, survival, and synaptic plasticity (Mattson and Camandola 2001). NF-kB levels were found to be higher in rats following fluid percussion and controlled cortical impact head injury, and also in biopsies of human contused neural tissue (Yang et al. 1995; McKeating and Andrews 1998).

**Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT)** JAK/STAT pathway is the fundamental channel intended for transmission of growth factors and cytokines accountable for variety of biochemical processes including axon regeneration, inflammation, cell differentiation, proliferation, and death (Oliva et al. 2012). Activation of JAK-STAT pathway commenced with a particular ligand binding to receptor on cellular surface, which subsequently triggers internal transmission via JAK kinase recruitment. JAK triggers dimerization and expression of STAT components. Some STAT proteins are found in nucleus and regulate gene expression by binding to a specific DNA sequence. After TBI, inflammatory process decreases JAK/STAT expression, resulting in increased cell death in cortical pericontusional region (Oliva et al. 2012). After TBI, rat peri-injured cortex cells were treated with recombinant erythropoietin (rhEPO), which increased JAK2 and STAT3 phosphorylation and reduced apoptosis. The JAK2 inhibitor AG490 lowered pJAK2 and pSTAT3 levels while increasing mRNA expression of many apoptosis-associated genes, implying that JAK2-STAT3 pathway is activated (Zhao et al. 2011) (Table 1).

**Mitogen-Activated Protein Kinase (MAPK) Pathway** MAPK is a threonine/serine-dependent protein kinase which is triggered by phosphorylation in response to diverse cells trauma. It is important for cell differentiation, proliferation, and survival. Cascades are made up of c-Jun NH (2)-terminal kinase (JNK), extracellular signal-regulated protein kinase (ERK), and p38. Numerous studies reported that activation of p38 and JNK pathway elevates neuronal damage accompanying spinal cord injury and cerebral ischemia (Otani et al. 2002). Following TBI, cell line-based studies revealed astrogial growth and fast ERK activation (Carbonell and Mandell 2003). Pathophysiology of TBI includes abnormalities in the MAPK signalling pathway and studies revealed that blocking this cascade improved cell survival rate and significantly reduces intensity of cortical lesions. JNKs are stress stimulated protein kinases that are found in nucleus of neuronal cells and are linked to neurodegeneration. TBI can activate JNK and cause a complex cascade in mitochondria of brain cells, resulting in apoptosis (Chi et al. 2013; Dietrich and Bramlett 2016) (Fig. 1).

**PI3K/Akt/mTOR Signalling Pathway** During brain development, the PI3K/Akt/mTOR signalling cascade is an important regulator of neuronal cell proliferation, axon outgrowth, and dendritic formation (Kumar 2005). Various hormones and growth factors that affect mTOR complex and target molecules like mTORC1 and mTORC2 induce downstream Akt and activation of PI3K (Dibble and Cantley 2015). mTOR integrates input from various upstream signals to control cell death, cell growth inhibition, and autophagy. mTOR regulates synthesis of proteins in axons and cell bodies, which are necessary for cell development. TBI-associated symptoms like inflammatory reactions and epilepsy are mostly controlled by inhibiting mTOR pathway (Guo et al. 2013).

**Glycogen synthase kinase 3 (GSK-3)** GSK-3 controls protein synthesis, microtubule dynamics, glycoprotein metabolism, cell differentiation apoptosis, and cell death. Wnt and Akt are two important signalling pathways that regulate GSK-3β activity and are also known as protein kinase B (Fang et al. 2000). Due to Akt activation, phosphorylation of GSK-3β induces response of pro and anti-inflammatory in monocytes. Exclusive GSK-3β inhibitors provide protection to cells from proapoptotic stimulus depending on the role of GSK-3β in apoptosis. Irregular stimulation of GSK-3β is associated with chronic neuroinflammation.
## Table 1  Inflammatory mediators involved in secondary injury in TBI

| Inflammatory mediators                  | Level with time of injury                                                                 | Mechanisms/comments                                                                                       | References                                                                                   |
|-----------------------------------------|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| **Cytokines and chemokines**            |                                                                                          |                                                                                                          |                                                                                               |
| Interleukin-1β                          | Within hours of a TBI, there is a rapid elevation. Peaks on days 1–2 and then drops off on days 2–4 | Activating other proinflammatory pathways such as TNF-α                                                  | Hutchinson et al. (2007)                                                                        |
| Interleukin-6                           | Peaks on day 1, decrease on days 2–3                                                      | Stimulate NGF production by astrocytes and post-traumatic tissue repair and aggravates blood–brain barrier function | Maas et al. (2010); Winter et al. (2002); Kossmann et al. (1996); Swartz et al. (2001); Winter (2004) |
| Interleukin-8                           | It stays raised for up to 4 days after an injury, with a peak on first day and a gradual fall on days 2 and 3 | Promotes neutrophil infiltration and increases BBB dysfunction                                           | Morganti-Kossmann et al. (1997); Whalen et al. (2000); Maier et al. (2001)                      |
| Interleukin-10                          | Levels rise quickly after TBI and stay high for several days before gradually declining | Through a variety of signalling channels, IL-10 promotes glial and neuronal cell survival and also reduction in inflammatory responses | Bell et al. (1997); Pinteaux et al. (2002); Basu et al. (2002), Stover et al. (2000); Tehranian et al. (2002) |
| Monocyte chemoattractant protein (MCP-1)| Peaks on first day, then drops and peaks by fourth day, but remains elevated until tenth day | Promotes macrophage infiltration                                                                       | Rothwell (2003); Stirling (2004); Xu et al. (2004); Maier et al. (2005); Semple et al. (2009)     |
| Transforming growth factor -β (TGF-β)   | Peaks at day 1 and slowly decrease after 21 days                                          | TGF-β plays a regulatory function in nerve regeneration by regulating immunological response, cellular activity, scar formation and neurite outgrowth | Morganti-Kossmann et al. (1999)                                                                 |
| Tumour necrosis factor (TNF-α)          | TNF-α expression increase within one hour following TBI, peak around 3 to 8 h and function normally within 24 h | Activation of microglia and astrocytes, influence blood brain barrier permeability, glutamatergic transmission and synaptic plasticity | Tuttolomondo et al. (2014)                                                                       |
| **Cellular mediators**                  |                                                                                          |                                                                                                          |                                                                                               |
| Astrocytes                              | Marker for reactive astrocytes (YKL-40)day 1 recorded an increase, while day 4 reaches at peak | Aggravate neuronal deterioration and transgenic depletion of reactive astrocyte                         | Myer et al. (2006); Bonneh-Barkay et al. (2010)                                                  |
| Microglia                               | Rapid elevation observed after 72 h of injury, Peaks at 3 months                          | Release of oxidative metabolites such as reactive oxygen, nitric oxide and nitrogen species and pro-inflammatory cytokines (e.g. interleukin (IL)-1β, tumour necrosis factor-β (TNFβ) and interferon-γ (IFNγ)) | Engel et al. (2000); Block and Hong (2005)                                                       |
| **Triggers and brakes**                 |                                                                                          |                                                                                                          |                                                                                               |
| Adenosine                               | Increased within hours of damage, then dropped quickly after 12–24 h                     | Triggers neuroinflammatory responses such as activating microglia and triggering P2X7R-mediated inflammation | Bell et al. (1998); Davalos et al. (2005); Jassam et al. (2017); Liu et al. (2017a)               |
| Complement                              | Peaks 1 day after injury, then declines during next 2–7 days                             | Promote neurogenesis and plasticity subsequent to brain injury                                         | Kossmann et al. (1997)                                                                         |
| Glutamate                               | Typically peak observed at day 1, decrease at days 2–3                                   | Activate three different groups of metabotropic receptors                                              | Chamoun et al. (2010); Niswender and Conn (2010)                                                |
and neurodegeneration. Several researches have shown that GSK-3β has a role in TBI models of neuroinflammation and also showed the potency of numerous inhibitors of GSK-3β in TBI (Li et al. 2014; Llorens-Martíñ et al. 2014).

Nuclear Factor Erythroid 2-Related Factor 2 Pathway

Nrf2 is a gene transcription component which protects cells from a variety of damaging stimuli. Nrf2 is mostly found in the cytoplasm, attached to its inhibitor Keap1, which restricts Nrf2 from entering the nucleus. In a recent study, it was found that Nrf2 downregulation promotes neuronal death and neuroinflammation by increasing oxidative stress, TGF-β1, NF-kB, and MMP3/9 (Suzuki and Yamamoto 2017).

Rho-GTPase Pathway

Rho-GTPases (Cdc42, Rac1, and RhoA) are principal regulators of cell adhesion and cytoskeletal and cell adhesion controlling a wide order of cellular processes (Chi et al. 2013). Rho GTPase signalling dysregulation has been associated with aetiology of amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease (Mulherkar and Tolias 2020). Continuous over expression of functional RhoA degrades neuritis repair and axonal regeneration following TBI, since it inhibits axonal regeneration as well as apoptotic responses. Astrocyte activation and proliferation are common responses to CNS damage (Mulherkar and Tolias 2020). The progressive formation of a scar-like structure by astrocytes, oligodendrocytes, microglia fibroblasts, and meningeal cells limits axonal regeneration and slows TBI recovery. In lateral fluid percussion injury model, RhoA activation has been observed in ipsilateral brain of rat (Dubreuil et al. 2006). Furthermore, it was also observed that RhoA activity was increased in neuroglia and spinal cord of rats and mice in rodent models of spinal cord injury models (Wu and Xu 2016).

TGF-β1 Signalling Pathway

Microglial inactivation is characterized by TGF-β signalling. TGF-β1 has been shown to play a protective role in CNS diseases in previous research. Taylor et al. discovered that this pathway enhanced functional improvement after intracerebral haemorrhage by altering microglial cell alternative stimulation (Taylor et al. 2016).

Nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) Pathway

It is a multi-protein complex which aggregates and activates caspase-1 in response to hazardous stimuli and promotes release of the pro-inflammatory cytokines IL-1β and IL-18. Following TBI, immune system activated by these cytokines produces neuroinflammation that contributes to cell death (Lamkanfi et al. 2011).

### Anti-inflammatory drugs and TBI

Glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) are primarily commercially available synthetic anti-inflammatory drugs. Glucocorticoids have potent
Immunosuppressive and anti-inflammatory properties. They suppress preliminary signs of inflammation like redness, discomfort, and swelling as well as the later stages of wound healing and its proliferative processes that occur in chronic inflammation. Indeed, steroids bind to certain intracellular receptors, forming a complex that later on modulates gene expression, inducing some proteins to be synthesized while others are inhibited (Barnes and Adcock 1993). Glucocorticoids also interact with AP-1, a heterodimer of Fos and Jun proteins that acts as a transcription factor activator. Inhibition of AP-1 inhibits the activity of leukocytes, lymphocytes, and mononuclear cells, as well as the release of pro-inflammatory cytokines including TNF-α and IL-2. Steroids also suppress COX-2 expression, a gene that is ordinarily activated by inflammatory mediators and produces inflammatory prostanooids. In addition, they prevent osteocalcin production in osteoblasts stimulated by vitamin D3. Also, steroids alter collagenase expression and diminish the production of lipocortin 1 (Barnes and Adcock 1993).

NSAID is a class of drugs having combined analgesic, antipyretic, and anti-inflammatory actions due to their inhibitory effect against cyclooxygenase (COX) enzyme. This COX inhibition remarkably reduces the level of IL-1β and also impedes IL-6 synthesis by modulating vasodilator prostaglandin synthesis pathways. Moreover, NSAIDs also inhibit calcium-dependent glutamate release which consequently attenuates glutamate-induced neurotoxicity (Breitner 1996).

Fig. 1 Various signalling pathways that affect the human brain (primarily neurons) in TBI

Most importantly, certain NSAIDs (e.g. aspirin, naproxen, ibuprofen, diclofenac, nabumetone, oxaprozin, and sulindac) also impede COX-1 enzyme causing unwanted adverse effects. However, novel compounds, on the other hand, work selectively on COX-2 and are thought to be more effective. Celecoxib and rofecoxib, two novel anti-inflammatory medicines, are designed to target inflammatory sites alongside protecting non-inflamed areas where COX-mediated prostaglandin generation may be advantageous (Leveugle and Fillit 1994; Lehmann et al. 1997; Ricote et al. 1998).

Another aspect of NSAIDs is that they stimulate the proliferator-activated receptor (PPAR), which causes transcriptional regulatory effects that decrease a variety of pro-inflammatory chemicals and microglial activity. Furthermore, several NSAIDs have antioxidant properties and inhibit NF-kB activation (Grilli et al. 1996) (Table 2).

Anti-inflammatory herbal drugs and TBI

Both crude plant extracts and their isolated compounds have shown neuroprotective effects on nerve functions due to their anti-inflammatory and antioxidant properties. Plant extracts used in traditional system for the alleviation of pain, fever, and inflammation have found to contain several natural anti-inflammatory medicines. A few of these natural products’ processes have been partially explored in recent years, and they are currently considered for therapy of chronic inflammatory and neurodegenerative illnesses. The majority of these medicines work by suppressing COX-2 transcription instead of activity. They also inhibit the expression of a number of pro-inflammatory genes (Keshavarzi et al. 2019).

Recently, numbers of traditional supplements and herbal medicine have been studied in treatment of TBI. Both animal and cellular TBI models revealed elevated expression of NF-κB, TNF-α, IL-6, and IL-1. Treatment with osthol, a coumarin derivative derived from Cnidium monnieri, reduced inflammatory mediators and enhanced neurological functions alongside elevating the neuronal count surrounding the injured area. Furthermore, treatment with osthol lowered...
Table 2  Anti-inflammatory drugs showing pharmacological potential in TBI

| Sr. No | Drugs (Animal Models)                     | Dose                                      | Outcomes of the study                                                                 | References                 |
|--------|-------------------------------------------|-------------------------------------------|---------------------------------------------------------------------------------------|----------------------------|
| 1      | Dexamethasone (Weight drop)               | 1 mg/kg, (i.p.) administered in rats after 5 min of injury | At days 1 and 2, but not at days 4 and 6, the expression of endothelial-monocyte activating polypeptide II, P2X4 receptor and allograft-inflammatory factor-1 suppressed | Zhang et al. (2007)        |
| 2      | Ibuprofen (Fluid percussion injury)       | 60 mg/kg, (i.p.) administered in mice after 5 min of injury | Cognitive function improved in NSS and rota rode at 24 h and 1 day of injury           | Harrison et al. (2014)     |
| 3      | Rofecoxib (Fluid percussion injury)       | 10 mg/kg, (i.p.) administered in rats after 5 min of injury | Neuroprotective effect observed at 12–72 h of injury in hippocampus region of brain    | Kunz et al. (2022)         |
| 4      | Nimesulide (Weight drop)                  | 6 mg/kg, (i.p.) administered in mice after 10 min of injury | Cognitive and motor function improved at 24 h after injury                             | Cernak et al. (2002)       |
| 5      | Celecoxib (Controlled cortical impact)     | 50 mg/kg, (p.o.) administered prior to injury in mice | IL-1 was inhibited, whereas the anti-inflammatory cytokine IL-10 was unchanged         | Dash et al. (2000)         |
| 6      | Carprofen (Weight drop)                   | 5 mg/kg, (s.c.) administered immediately after injury in mice | Inhibition of microglial activation, improvement in neurological function, induces cell proliferation and gliogenesis after TBI | Thau-Zuchman et al. (2012) |
| 7      | Meloxicam (Weight drop)                   | 2 mg/kg, (i.p.) administered in rats after 30 min of injury | ▼Brain oedema and lipid peroxidation                                                  | Hakan et al. (2010)       |
| 8      | Etanercept (Fluid percussion injury)       | 5 mg/kg, (i.p.) administered in rats immediately after injury | ▲Motor and neurological function, ▼IL-6 and IL-1β level after 3 days of injury and ▼TNF-α at both 3 and 7 days post-injury | Chi et al. (2013)          |
| 9      | 3,6′-dithiothalidomide (Weight drop)      | 28 mg/kg, (i.p.) administered in mice before 1 h of injury | Inhibit TNF-α synthesis and ▲cognitive function                                         | Baratz et al. (2011)      |
| 10     | Anakinra (Controlled cortical impact)      | 100 mg/kg, (i.p.) administered in rats after 2 h of injury | Decreases endogenous IL-1rn gene expression only for 24 h, with no impact following 72 h and 7 day | Anderson et al. (2013)     |
| 11     | Etazolate (Weight drop)                   | 10 mg/kg (i.p.) administered in mice after 2 h of injury | ▼Microglia, IL-1β, oedema and NSS                                                     | Siopi et al. (2013)       |
| 12     | Salsalate (Controlled cortical impact)     | 50 mg/kg (i.p.) injected in mice after 30 min of injury and once daily for five consecutive days | ▼Activation of NF-kB, ▼nitrite secretion by microglia and ▲cognitive function, expression of genes linked with neurogenesis and neuroprotection | Lagraoui et al. (2017)    |
the production of numerous inflammatory mediators (Kong et al. 2019).

We evaluated previous study to analyse possible neuroprotective effect of several medicinal plants in brain injury, owing to the increasing number of research published in recent years. Medicinal plants included in Table 3 have shown pharmacological potential in different model of TBI.

| Sr. No | Plant (phytoconstituent/extract) | Dose/Model | Mechanism | References |
|--------|----------------------------------|------------|-----------|------------|
| 1      | Actaea racemosa (Formononetin)   | 10 and 30 mg/kg, Weight drop | ↑ IL-10, ↓ IL-6 and TNF-α | Baez-Jurado et al. (2017) |
| 2      | Artemisia annua (Atesunate)      | 30 mg/kg, Controlled cortical impact | ↓ Inflammation, level of TNF-α, IL-1β, VEGF, BDNF, GDNF and iNOS | Gugliandolo et al. (2018) |
| 3      | Cinnamomum zeylanicum (Polyphe-nol E) | 10 mg/kg, Controlled cortical impact | ↓ NF-κB, IL-6, IL-1, NCAM, Nrf2 and GFAP expressions | Yulug et al. (2018) |
| 4      | Crocus sativus (Crocin)          | 20 mg/kg, Controlled cortical impact | ↓ Activation of microglia, cell apoptosis, TNF-α and IL-1β | Wang et al. (2015) |
| 5      | Panax ginseng (Aqueous extract)  | 50, 100, and 200 mg/kg, Weight drop | ↓ Expression of TNF-α, MDA, AChE, nitrite and ↑ IL-6, SOD, GSH | Kumar et al. (2013) |
| 6      | Malva sylvestris (Methanolic extract) | 250 and 500 mg/kg, Controlled cortical impact | ↓ Neuronal loss, synthesis of ROS, expression of TNF-α, IL-6, IL-1β, and LPO ↑ SOD | Qin et al. (2017) |
| 7      | Salvia tomentosa (Luteolin)      | 20 mg/kg, Controlled cortical impact | ↓ TNF-α and IL-1β | Sawmiller et al. (2014) |
| 8      | Dracaena cochinchensis (Aqueous extract) | 40 and 80 mg/kg, Weight drop | ↓ MDA, IL-1β, IL-6, TNF-α and cell apoptosis | Hu et al. (2018) |
| 9      | Rosmarinus officinalis (Aqueous extract) | 40, 80, and 160 mg/mL, Lateral fluid percussion | ↓ ROS generation, GFAP-positive cells, level of IL-1β, TNF-α and IL-6 | Gohil et al. (2010) |
| 10     | Curcuma longa (Curcumin)         | 75, 150, and 300 mg/kg, Controlled cortical impact | ↓ Cerebral oedema, level of AQP4 and IL-1β, activation of NF-κB ↑ neurological function | Momtazi et al. (2016) |
| 11     | Curcuma zedoaria (β-Elemene)     | 100 mg/kg, Weight drop | ↓ TNF-α, IL-1β, TLR-4, cell apoptosis ↑ neurological severity score | Samini et al. (2013) |
| 12     | Drynaria fortune (Aqueous extract) | 20 mg/kg, Controlled cortical impact | inhibited microglial/macrophage activation, ↓ brain lesion volume and IL-6 ↑ IL-10, neurological severity score and cognitive function | Vosough-Ghanbari et al. (2010) |
| 13     | Salvia miltiorrhiza (Salvianolic acid) | 25 mg/kg, Controlled cortical impact | ↓ TNF-α and IL-1β ↑ IL-10, TGF-β1 and neurological function | Singh et al. (2013) |
| 14     | Satureja khuzistanica (essential oil) | 50, 100, and 200 mg/kg, Weight drop | ↓ BBB permeability, intracranial pressure, neuronal cell death, level of TNF-α, IL-1β and IL-6 ↑ numbers of viable astrocyte and IL-10 level | Meng et al. (2018) |
| 15     | Scutellaria baicalensis (Baicalein) | 30 mg/kg, Controlled cortical impact | ↓ degenerating neuronal count, TNFαr, IL-6 and IL-1β expressions ↑ neurological functions | Wang et al. (2015) |
| 16     | Cnidium monnieri (Osthole)       | 10–40 mg/kg, Weight drop | ↓ inflammatory mediators, hippocampal neuron loss, cerebral oedema and neurological function, SOD, MDA, GSH Bcl-2/Bax and active caspase-3 level | He et al. (2012) |
Anti-inflammatory drugs and neuroprotective potential in TBI

Anti-inflammatory approaches to prevent and treat neurotoxicity-associated neurological diseases have proved effective in vast cell-based and pre-clinical models, although nothing has been confirmed in later stages of clinical evaluations. However, with conclusive experiments this therapeutic approach propounds encouraging prospects for clinical exploration. In experimental animal models of stroke, both glucocorticoids and general anaesthetic drugs have sparked a great attention in neuroprotection; however, this has yet to be proved in humans (Degos et al. 2022). At some stage of stroke, head trauma, and meningeal bleeding, glucocorticoids have been, however, reported to be ineffective. Classic hypnotics such as thiopental and midazolam have immune-modulating properties and can reduce inflammatory responses in the peripheral nervous system. In an experimental mouse model, they suppress chemotaxis, neutrophil adherence, and phagocytosis as well as impede the discharge of free radicals and pro-inflammatory cytokines; however, these activities have yet to be proven in humans. COX inhibitors (mainly nimesulide and indomethacin) exhibit neuroprotective activity in neonatal mice with brain lesions (Muller 2019). The communication repression between the brain and activated peripheral inflammatory cells through blood–brain barrier induces neuroprotective action. Moreover, COX inhibitors are also reported remarkably effective against depression and various other psychiatric disorders. Noteworthy, celecoxib has been affirmed as an effective drug to treat serious depression and schizophrenia, predominantly in the early stages. Furthermore, acetyl salicylic acid has demonstrated preventative and curative effect against schizophrenia (Degos et al. 2022; Muller 2019).

Current status of anti-inflammatory drugs in management of TBI

Despite advancements in preventative, diagnostic, and surgical techniques, therapeutic choices have been limited for management of TBI. Till date, no pharmacological remedy has been found to provide neuroprotective effects by targeting secondary damage mechanisms (Lozano et al. 2015).

Rehabilitation therapy is used in the majority of the patients. Because damage caused by initial injury is nearly impossible to treat, the rational approach for therapy intervention that provides clinically relevant advantages is to prevent subsequent cell death. It provides a large treatment window due to a delay in harm caused by secondary cell death (Lozano et al. 2015). Targeting neuroinflammation among the secondary wave of biochemical pathways appealed to this extended time for intervention beginning.

A variety of medications have been examined and reported to decrease inflammation in animals and TBI patients at the preclinical and clinical levels.

A systematic analysis was performed through US National Institutes of Health clinical trials database using various search strategy consisting of either single or combination of the following keywords: traumatic brain injury, anti-inflammatory drugs, COX-1, COX-2, and specific names of distinct anti-inflammatory drug such as aspirin, celecoxib, ibuprofen, diclofenac. However, no specific findings are obtained in relevance to intervention of anti-inflammatory drugs in prognosis of traumatic brain injury. Although the use of dexamethasone in prognosis of TBI patients with brain contusions and pericontusional oedema is under recruiting status of phase 3, hopefully it will give expected outcomes.

Some clinical evidences suggested certain clinically approved drugs having potential anti-inflammatory activity are used in the treatment of TBI and some are under clinical trials as mentioned in Table 4. Meta-analysis study by Begemann et al. (2020) affirms that TBI patients receiving progesterone, erythropoietin, or cyclosporine have higher chance of a favourable outcome comparatively to those receiving placebo.

Challenges with anti-inflammatory drugs

Clinical trials including anti-inflammatory drugs have produced mixed outcomes so far. Nonselective COX inhibition, inadequate use of specific anti-inflammatory medicines for a given illness or illness progression/severity, sub-optimal dosing at specified location, or inadequate transmission through BBB to brain could all be reasons for varied outcomes (Gilgun-Sherki et al. 2006).

Long-term use of high-dose NSAIDs has been linked to the development of autoimmune disorders. The use of NSAIDs in TBI models is currently investigated; however, the results have been equivocal thus far. In a pre-clinical study, chronic ibuprofen treatment significantly increased cognitive and histological outcome. However, it failed to provide neuroprotection in a TBI model (Harrison et al. 2014).

Prolonged administration of ibuprofen in injured animals provides a much lower results as compared to placebo. Moreover, no significant differences in tissue atrophy level in hippocampus or cortex between treated and untreated mice were observed. These data imply that using high dosages of anti-inflammatory drugs for an extended length of time after trauma may diminish the neuroprotective effects of post-traumatic inflammatory cytokines (Harrison et al. 2014).
Summary

Multiple studies in animal models of TBI have shown that neuroprotective therapies can reduce subsequent damage processes and/or enhance behavioural outcomes. However, none of these promising experimental neuroprotective treatments have been translated to improve clinical outcomes in human. As a result, the development of new anti-inflammatory medications for the treatment of neurodegenerative illnesses that are based on improved BBB transit and have a higher safety profile could result in beneficial therapy. Moreover, the heterogeneity of population genetics and the degree of pathology should be considered while developing novel anti-inflammatory medications. To truly understand the process and chemistry of anti-inflammatory drug delivery into the brain, more research is required. Hence, to decrease this native risk, more specific methods are required to modulate the inflammation. Inflammasome inhibition will be one approach. This technique, however, remains difficult due to a lack of or insufficient understanding of inflammasome structure and activation. Nonetheless, some research on psychiatric disorders has focused at inhibiting NLRP3, the best studied inflammasome. This antagonist endogenously formed after brain injury, and it reduces lesion size in animal models when administered systemically or intracerebrally. To conclude, neuroprotection strategies based on inflammation modulation must maintain the immunological defense and curative functions of inflammation along with eliminating its neurotoxic effects; as a result, three major anti-inflammatory approaches for the neuroprotection pathway can be evolved: modification of peripheral inflammation-CNS communication, modification of pro-inflammatory cytokines—intracerebral targets interaction, and modification of inflammasome production in brain cells.

Author contributions SK, RM, and GS involved in conceptualization; SK, SB, SM took part in original draft preparation; HAM and MA took part in literature review; SK, RM, GS, SB, AA took part in writing, review, and editing; LA, GS, and SB took part in proof reading.

Funding The present review did not receive any funding.

Availability of data and materials Information/data collected from open sources.

Declarations

Competing interests The author(s) declare that they have no conflict of interest.

Ethical approval Not applicable.

Consent to participate Not applicable.

Consent to publish All the authors have approved the manuscript for publication.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in

Table 4 Anti-inflammatory drugs under clinical phases for TBI management

| Sr. No | Drug          | Type of study                                      | Proposed mechanism                                                                                                                   | Status          |
|--------|---------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 1      | Erythropoietin| Erythropoietin long term effect observed in patients which suffered from moderate to severe injury | Showed anti-inflammatory, antiapoptotic and anti-oedematous properties due to stimulation of JAK/STAT pathway                      | Phase III       |
| 2      | Rosuvastatin  | After TBI, rosuvastatin effects studied on cytokines | Modulates TNF-α, IL-1, and IL-6 to change the immune response following brain injury                                                    | Phase II completed |
| 3      | Progesterone  | Progesterone for Treatment of TBI III (ProTECT)   | Neuronal loss and cerebral oedema reduced, remyelination is improved, functional recovery is improved after progesterone infusion     | Terminated at Phase III |
| 4      | Methylprednisolone | Infusion of Methylprednisolone for 24 or 48 h vs. Tiramazol for acute spinal cord injury | Suppress NF-kB activation and TNF-α expression                                                                                       | Phase III completed |
| 5      | Minocycline   | Minocycline’s safety and efficacy in the treatment of TBI | IL-1β and Microglial activation reduced                                                                                             | Ongoing phase 1/II |
| 6      | N-acetyl cysteine | The safety and potential therapeutic efficacy in mild blast traumatic brain injury patients | Reduces neurological symptoms                                                                                                         | Phase II         |
| 7      | Anakinra      | Study for moderate to severe TBI patients         | Decrease in pro-inflammatory cytokines for first 48 h of injury                                                                       | Phase II         |
References

(2022) In: Academicjournals.org. https://academicjournals.org/article/article1380714402_Wang.pdf. Accessed 18 Apr 2022

(2022) In: Gpb.sav.sk. http://www.gpb.sav.sk/2002_03_231.pdf. Accessed 18 Apr 2022

Anderson G, Peterson T, Vonder Haar C, Kantor E, Farin F, Bammler T, MacDonald J, Hoane M (2013) Comparison of the effects of erythropoietin and anakinra on functional recovery and gene expression in a traumatic brain injury model. Front Pharmacol. https://doi.org/10.3389/fphar.2013.00129

Baez-Jurado E, Vega G, Aliev G, Tarasov V, Esquinas P, Echeverria V, Barreto G (2017) Blockade of neuroglobin reduces protection of conditioned medium from human mesenchymal stem cells in human astrocyte model (T98G) under a scratch assay. Mol Neurobiol 55:2285–2300

Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 14(12):436–441. https://doi.org/10.1016/0165-6147(93)90184-I

Baratz R, Tweedie D, Rubovitch V, Luo W, Yoon J, Hoffer B, Greig Barnes PJ, Adcock I (2010) Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. J Neurosurg 113:564–570

Chi X, Wang S, Huang Y, Stannes M, Chen J (2013) Roles of rho GTPases in intracellular transport and cellular transformation. Int J Mol Sci 14:7089–7108

Dash P, Mach S, Moore A (2000) Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury. J Neurotrauma 17:69–81

Davalos D, Gutzendiller J, Yang G, Kim J, Zuo Y, Jung S, Littman D, Dustin M, Gan W (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8:752–758

Degos V, Chhor V, Gressens P, Mantz J (2022) Neuro-inflammation aigue et strategies neuroprotectrices. Accessed 18 Apr 2022

Dibble C, Cantley L (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 25:545–555

Dietrich W, Bramlett H (2016) Therapeutic hypothermia and targeted temperature management in traumatic brain injury: clinical challenges for successful translation. Brain Res 1640:94–103

Dubreuil C, Marklund N, Deschamps K, McIntosh T, McKerracher L (2006) Activation of Rho after traumatic brain injury and seizure in rats. Exp Neurol 198:361–369

Engel S, Schluesener H, Mittelbronn M, Seid K, Adjodah D, Wehner H, Meyermann R (2000) Dynamics of microglial activation after human traumatic brain injury are revealed by delayed expression of macrophage-related proteins MR8 and MRP14. Acta Neuropathol 100:313–322

Fang X, Yu S, Lu Y, Bast R, Woodgett J, Mills G (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci 97:11960–11965

Gilgun-Sherki Y, Melamed E, Offen D (2006) Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Curr Pharm Des 12:3509–3519

Gohil K, Patel J, Gajjar A (2010) Pharmacological review on Centella asiatica: a potential herbal cure-all. Indian J Pharm Sci 72:546

Grilli M, Pizzi M, Memo M, Spano P (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274(5291):1383–1385. https://doi.org/10.1126/science.274.5291.1383

Gugliandolo E, D’Amico R, Cordaro M, Fusco R, Siracusa R, Crupi R, Impellizzeri D, Cuzzocrea S, Di Paola R (2018) Neuroprotective effect of artemisinin in experimental model of traumatic brain injury. Front Neurol. https://doi.org/10.3389/fneur.2018.00590

Guo D, Zeng L, Brody D, Wong M (2013) Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS ONE 8:e64078

Hakan T, Toklu H, Biber N, Ozevren H, Solakoglu S, Demirturk P, Aker F (2010) Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood–brain barrier permeability. Neurol Res 32:629–635

Hammad A, Westacott L, Zaben M (2018) The role of the complement system in traumatic brain injury: a review. J Neuroinflammation. https://doi.org/10.1186/s12974-018-1066-z

Harrison J, Rowe R, O’Hara B, Adelson P, Lifshitz J (2014) Acute over-the-counter pharmacological intervention does not adversely affect behavioral outcome following diffuse traumatic brain injury in the mouse. Exp Brain Res 232:2709–2719

Carbonell W, Mandell J (2003) Transient neuronal but persistent astrogliial activation of ERK/MAP kinase after focal brain injury in mice. J Neurotrauma 20:327–336

Cernak I, O’Connor C, Vink R (2002) Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats. Exp Brain Res 147:193–199

Chamoun R, Suki D, Gopinath S, Goodman J, Robertson C (2010) Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. J Neurosurg 20:327–336

Harrison J, Rowe R, O’Hara B, Adelson P, Lifshitz J (2014) Acute over-the-counter pharmacological intervention does not adversely affect behavioral outcome following diffuse traumatic brain injury in the mouse. Exp Brain Res 232:2709–2719
Hutchinson P, O'Connell M, Rothwell N, Hopkins S, Nortje J, Car-Hu W, Chan G, Lou J, Wu Q, Wang H, Duan R, Cheng M, Dong T, He Y, Qu S, Wang J, He X, Lin W, Zhen H, Zhang X (2012) Neuro-Haynes S, Hollopeter G, Yang G, Kurpius D, Dailey M, Gan W, Julius 1164 S. Kalra et al.

1164 S. Kalra et al.

Hutchinson P, O’Connell M, Rothwell N, Hopkins S, Nortje J, Carpenter K, Timofeev I, Al-Rawi P, Menon D, Pickard J (2007) Inflammation in human brain injury: intracerebral concentrations of IL-1α, IL-1β, and their endogenous inhibitor IL-1α. J Neurotrauma 24:1545–1557

Jassam Y, Izy S, Whalen M, McGavren D, El Khoury J (2017) Neuro-immunology of traumatic brain injury: time for a paradigm shift. Neuron 95:1246–1265

Keshavarzi Z, Shakeri F, Barreto G, Bibak B, Sathyapalan T, Sehebark A (2019) Medicinal plants in traumatic brain injury: Neuroprotective mechanisms revisited. BioFactors 45:517–535

Kong L, Yao Y, Xia Y, Liang X, Ni Y, Yang J (2019) Osthole alleviates inflammation by down-regulating NF-κB signaling pathway in traumatic brain injury. Immunopharmacol Immunotoxicol 41:349–360

Kossmann T, Hans V, Imhof H, Trentz O, Morganti-Kossmann M (1996) Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Res 713:143–152

Kossmann T, Stahel P, Morganti-Kossmann M, Jones J, Barnum S (1997) Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J Neuroimmunol 73:63–69

Kumar V (2005) Regulation of dendritic morphogenesis by ras-PI3K-Akt-mTOR and ras-MAPK signaling pathways. J Neurosci 25:11288–11296

Kumar A, Rinao P, Dhar H (2013) Microglial inhibitory effect of ginseng ameliorates cognitive deficits and neuroinflammation following traumatic head injury in rats. Inflammopharmacology 22:155–167

Kunz T, Marklund N, Hillered L, Olov EH (2022) Effects of the selective cyclooxygenase-2 inhibitor rofecoxib on cell death following traumatic brain injury in the rat. In: PubMed. https://www.ncbi.nlm.nih.gov/pubmed/16518028, Accessed 18 April 2022

Lagrou M, Sukumar G, Latoche JR, Maynard SK, Dalgard CL, Schaefer BC (2017) Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain Behav Immun 61:96–109. https://doi.org/10.1016/j.bbi.2016.12.005

Laird M, Shields J, Sukumari-Ramesh S, Kimbler D, Fessler R, Shaksir B, Youssef P, Yang J, Dhandapani K (2013) High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia 62:26–38

Lamkanfi M, Walle L, Kanneganti T (2011) Deregulated inflammasome signaling in disease. Immunol Rev 243:163–173

Lehmann JM, Lennard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272(6):3406–3410. https://doi.org/10.1074/jbc.272.6.3406

Leveugle B, Fillit H (1994) Proteoglycans and the acute phase response in Alzheimer’s disease brain. Mol Neurobiol 9(1–3):25–32. https://doi.org/10.1007/BF02816102

Li D, Liu Z, Wei-Chen M-Y, Li G (2014) Association of glycogen synthase kinase-3β with Parkinson’s disease (Review). Mol Med Rep 9:2043–2050

Li D, Liu N, Zhao H, Zhang X, Kawano H, Liu L, Zhao L, Li H (2017) Interactions between Sirt1 and MAPKs regulate astrocyte activation induced by brain injury in vitro and in vivo. J Neuroinflammation. https://doi.org/10.1186/s12974-017-0841-6

Liu T, Zhang L, Joo D, Sun S (2017a) NF-κB signaling in inflammation. Signal Transduct Target Ther. https://doi.org/10.1038/sigtr ans.2017.23

Liu X, Zhao Z, Ji R, Zhu J, Sui Q, Knight G, Burnstock G, He C, Yuan H, Xiang Z (2017b) Inhibition of P2X7 receptors improves outcomes after traumatic brain injury in rats. Purinergic Signalling 13:529–544

Llorens-Maratin M, Jurado J, Hernández F, Ávila J (2014) GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. https://doi.org/10.3389/fnmol.2014.00046

Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, Brlongan CV (2015) Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatric Dis Treatment 8:119–126. https://doi.org/10.2147/NTD.S65815

Lucke-Wold B, Seidel K, Udo R, Omalu B, Ornstein M, Nolan R, Rosen C, Ross J (2017) Role of tau acetylation in Alzheimer’s disease and chronic traumatic encephalopathy: the way forward for successful treatment. Journal of Neurology and Neurosurgery 4(2):140

Maas A, Roozenbeek B, Manley G (2010) Clinical trials in traumatic brain injury: past experience and current developments. Neurol Rehabil 7:115–126

Maeda T, Kawane T, Horiiuchi N (2003) Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144:681–692

Maier B, Schwertfeger K, Mautes A, Holanda M, Müller M, Steudel W, Marzi I (2001) Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock 15:421–426

Maier B, Lauber H, Rose S, Buurman W, Marzi I (2005) Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma 22:822–835

Mattson M, Camandola S (2001) NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107:247–254

Mbye L, Singh I, Sullivan P, Springer J, Hall E (2008) Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog. Exp Neurol 209:243–253

McKeating E, Andrews P (1998) Cytokines and adhesion molecules in traumatic brain injury and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock 15:421–426

Meyer C, Shao P, Privat A, Ribotta M (2003) Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. Proc Natl Acad Sci 100:8999–9004

Meng X, Li N, Zhang Y, Fan D, Yang C, Li H, Guo D, Pan S (2018) Beneficial effect of β-elemene alone and in combination with hyperbaric oxygen in traumatic brain injury by inflammatory pathway. Transl Neurosci 9:33–37
growth factor from human brain in vivo. J Neurosci Methods 119:45–50
Xiong Y, Gu Q, Peterson P, Muizelaar J, Lee C (1997) Mitochondrial
dysfunction and calcium perturbation induced by traumatic brain
injury. J Neurotrauma 14:23–34
Xu X, Wu X (2016) RhoA/Rho kinase in spinal cord injury. Neural
Regen Res 11:23
Xu L, Fagan S, Waller J, Edwards D, Borlongan C, Zheng J, Hill W,
Feuerstein G, Hess D (2004) Low dose intravenous minocycline
is neuroprotective after middle cerebral artery occlusion-reperfu-
sion in rats. BMC Neurol. https://doi.org/10.1186/1471-2377-4-7
Yang K, Mu X, Hayes R (1995) Increased cortical nuclear factor-κB
(NF-κB) DNA binding activity after traumatic brain injury in
rats. Neurosci Lett 197:101–104
Yulug B, Kilic E, Altunay S, Ersavas C, Orhan C, Dalay A, Tuzcu M,
Sahin N, Juturu V, Sahin K (2018) Cinnamon polyphenol extract
exerts neuroprotective activity in traumatic brain injury in male
mice. CNS Neurol Disord Drug Targets 17:439–447
Zhao Z, Zhang Z, Artelt M, Burnet M, Schluesener H (2007) Dex-
amethasone attenuates early expression of three molecules
associated with microglia/macrophages activation following rat
traumatic brain injury. Acta Neuropathol 113:675–682
Zhao Z, Alam S, Oppenheim R, Prevette D, Evenson A, Parsadanian
A (2004) Overexpression of glial cell line-derived neurotrophic
factor in the CNS rescues motoneurons from programmed cell
death and promotes their long-term survival following axotomy.
Exp Neurol 190:356–372
Zhao J, Li G, Zhang Y, Su X, Hang C (2011) The potential role of
JAK2/STAT3 pathway on the anti-apoptotic effect of recombi-
nant human erythropoietin (rhEPO) after experimental traumatic
brain injury of rats. Cytokine 56:343–350

Publisher's Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.